Innovative Therapeutics QED Therapeutics is focused on developing targeted treatments for achondroplasia through its investigational drug infigratinib, presenting opportunities for partnerships or supply chain expansion in biotech and specialized pharmaceuticals.
Strategic Collaborations The company's global licensing and partnership agreements with Helsinn Group and Foundation Medicine highlight potential avenues for co-marketing, diagnostic development, and expanding the reach of its therapies.
Patient Support Platforms Recent launch of MyAchonJourney demonstrates QED's commitment to patient engagement, opening opportunities for sales of related medical devices, support services, or ancillary healthcare products targeting the achondroplasia community.
Funding & Growth With $65M in seed funding and revenue between $1M and $10M, QED is positioned for expansion and investment in R&D, offering potential sales opportunities in biotech infrastructure, laboratory equipment, and research services.
Market Potential As a subsidiary of BridgeBio Pharma with a focus on rare genetic disorders, QED presents opportunities for sales in precision medicine, diagnostics, and regulatory consulting tailored to rare disease therapies and clinical development.
$25M$50M
$250M$500M
$10B
$10M$25M
$10B
$10B
$100M$250MQED Therapeutics uses 8 technology products and services including SAS/STAT, Cloudflare, oEmbed, and more. Explore QED Therapeutics's tech stack below.
| QED Therapeutics Email Formats | Percentage |
| First.Last@qedtx.com | 93% |
| FLast@qedtx.com | 3% |
| FL@qedtx.com | 2% |
| First@qedtx.com | 2% |
Biotechnology ResearchCalifornia, United States11-50 Employees
QED Therapeutics, an affiliate company of BridgeBio Pharma, is dedicated to developing meaningful treatment options for those with achondroplasia and pursuing research to address the needs of the community. We are studying whether an investigational agent (infigratinib) has the potential to address the root cause of irregular bone growth in achondroplasia, by decreasing the overactivity of the FGFR3 receptor.
Company Overview
Media & News
Funding & FinancialsQED Therapeutics has raised a total of $65M of funding over 1 rounds. Their latest funding round was raised on Jan 30, 2018 in the amount of $65M.
QED Therapeutics's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsQED Therapeutics has raised a total of $65M of funding over 1 rounds. Their latest funding round was raised on Jan 30, 2018 in the amount of $65M.
QED Therapeutics's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com